The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Truist Securities on August 14, 2024. The analyst firm set a price target for $13.00 expecting SAGE to rise to within 12 months (a possible 50.29% upside). 50 analyst firms have reported ratings in the last year.

The latest analyst rating for Sage Therapeutics (NASDAQ:SAGE) was provided by Truist Securities, and Sage Therapeutics maintained their hold rating.

The last upgrade for Sage Therapeutics Inc happened on March 13, 2023 when RBC Capital raised their price target to $60. RBC Capital previously had a sector perform for Sage Therapeutics Inc.

The last downgrade for Sage Therapeutics Inc happened on July 30, 2024 when TD Cowen changed their price target from $16 to $10 for Sage Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a maintained with a price target of $18.00 to $13.00. The current price Sage Therapeutics (SAGE) is trading at is $8.65, which is out of the analyst’s predicted range.